Retatrutide
LY3437943
Retatrutide is a novel triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors for superior metabolic effects. This innovative approach produces enhanced appetite suppression, improved insulin sensitivity, and increased energy expenditure, potentially delivering 20-25% weight loss in clinical trials.
Retatrutide Dosing Guide
Primary Benefits
- Exceptional weight loss (up to 24.2% in trials)
- Superior appetite suppression through triple agonism
- Improved insulin sensitivity and glucose control
- Enhanced energy expenditure and fat oxidation
- Significant HbA1c reduction in diabetic patients
How It Works
Retatrutide functions as a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. GLP-1 receptor activation provides appetite suppression and glucose-dependent insulin secretion. GIP receptor engagement enhances insulin sensitivity and promotes satiety. Glucagon receptor stimulation increases energy expenditure and promotes fat oxidation. This synergistic triple mechanism creates superior metabolic effects compared to single or dual agonist therapies.
Quick Reference
Typical Dosage Range
Standard escalation begins with 2.4 mg weekly for 4 weeks, followed by 4.8 mg weekly for 4 weeks. Further increases to 7.2 mg and maximum 12 mg weekly should occur at 4-week intervals based on clinical response and tolerability. Most patients achieve optimal results at 7.2-12 mg weekly for weight management.
Administration Methods
Subcutaneous injection using pre-filled pens or vials with separate syringes. Injection sites include abdomen, thigh, or upper arm. Rotate injection sites weekly to prevent lipodystrophy. Administer on the same day each week, any time of day, with or without meals. If dose is missed, administer as soon as possible if within 4 days, otherwise skip and resume regular schedule.
Medical Disclaimer
Retatrutide is currently in Phase 3 clinical trials and is not yet FDA approved. This information is for educational purposes only and should not replace medical advice. Consult with healthcare providers familiar with investigational therapies for personalized guidance. Side effects and contraindications are based on available clinical trial data.